AMD3100 TO MOBILIZE PERIPHERAL BLOOD STEM CELLS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 确定使用G-CSF动员方案给药的AMD3100是否总体安全和耐受性良好。确定使用G-CSF动员方案的AMD3100是否会增加收集用于移植的外周干细胞的数量。 这是一个富有同情心的使用计划，尽管有相似之处，但无论是FDA(食品和药物管理局)还是AMD3100的制造商AnorMED都不认为它是一项研究研究。同情使用是一种为没有资格在临床试验中接受这种疗法，但患有严重或危及生命的疾病而没有其他治疗方法的患者提供实验性治疗的一种方式。然而，从这一同情使用计划中收集的信息将用于研究目的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Determine if AMD3100, given with a G-CSF mobilizing regimen is generally safe and well tolerated. Determine if AMD3100, given with a G-CSF mobilizing regimen will increase the number of peripheral stem cells collected for transplantation. This is a compassionate use program and although there are similarities, it's not considered a research study either by the FDA (Food and Drug Administration) or AnorMED, the manufacturer of AMD3100. Compassionate use is a way to provide experimental treatment to a patient who is not eligible to receive that therapy in a clinical trial, but who has a serious or life-threatening illness for which other treatments are not available. Information that is collected from this compassionate use program, however, will be used for research purposes.